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Photopheresis is a leukapheresis-based therapy that util-
izes 8-methoxypsoralen and ultraviolet A irradiation.
Photopheresis is currently available at approximately 150
medical centers worldwide. Recent evidence suggests
that this therapy used as a single agent may significantly
prolong life, as well as induce a 50%–75% response
rate among individuals with advanced cutaneous T cell
lymphoma (CTCL). Furthermore, a 20%–25% complete
response rate with photopheresis alone, or in combination
with other biologic response modifiers, has been obtained
at our institution among patients with Sezary syndrome.
These complete responses have been characterized by
the complete disappearance of morphologically atypical
cells from the skin and blood. The use of sensitive
molecular techniques has also confirmed the sustained
disappearance of the malignant T cell clone from the
blood of patients with complete responses. In addition
Extracorporeal photopheresis is a leukapheresis-basedimmunomodulatory therapy that has been approved bythe United States Food and Drug Administration since1988 for the treatment of advanced cutaneous T celllymphoma (CTCL). This therapy is presently available at
approximately 150 treatment centers world-wide. At many institutions,
photopheresis used with other biologic response modifiers has become
a primary therapy for leukemic forms of CTCL, particularly for the
Sezary syndrome that is characterized by erythroderma, circulating
malignant T cells, and lymphadenopathy. Long-term follow up of
patients who participated in the initial multicenter clinical trial con-
ducted by Edelson et al, as well as follow up of our own patients, has
indicated that photopheresis may be capable of producing significant
prolongation of life in comparison with historic controls with a similar
burden of disease (Edelson et al, 1987; Gottlieb et al, 1996). Moreover,
the potential for cure of advanced forms of this malignancy was also
realized during this trial as 25% of patients have experienced complete
remission, with as many as 10% having no detectable residual disease
for periods of up to 11 y.
In addition to therapy of CTCL, exciting recent results have
indicated that photopheresis can be an effective means of reversing
cases of resistant solid organ transplant rejection (Costanzo-Nordin
et al, 1992a; Dall’Amico et al, 1995; Slovis et al, 1995; Wolfe et al,
1996; Barr et al, 1998). Similarly, a high response rate of chronic graft
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to the treatment of CTCL, numerous reports indicate
that photopheresis is a potent agent in the therapy of
acute allograft rejection among cardiac, lung, and renal
transplant recipients. Chronic graft versus host disease
also appears to be quite responsive to photopheresis
therapy. Likewise, there may also be a potential role for
photopheresis in the therapy of certain autoimmune
diseases that are poorly responsive to conventional ther-
apy. The immunologic basis for the responses of patients
with these conditions is likely due to the induction
of anticlonotypic immunity directed against pathogenic
clones of T lymphocytes. Treatment-induced apoptotic
death of pathogenic T cells and activation of antigen
presenting cells are postulated to have important effects
in this therapeutic process. Key words: photopheresis/
transplantation/psoralen/lymphoma. Journal of Investigative
Dermatology Symposium Proceedings 4:85–90, 1999
versus host disease to photopheresis also suggests the usefulness of this
therapy in the post-bone marrow transplant setting (Greinix et al, 1999;
Dall’Amico et al, 1997). Finally, the results of a randomized, controlled
trial of the treatment of systemic sclerosis with photopheresis, as well
as results of several earlier pilot studies that involved the therapy of
pemphigus vulgaris and rheumatoid arthritis, also indicate the potential
utility of photopheresis in the therapy of immunosuppressive drug
resistant autoimmune disease (Rook et al, 1990, 1992; Malawista et al,
1991). In this review we will summarize the current use of photopheresis
to treat cutaneous T cell lymphoma, allograft rejection, and autoimmune
disease. Furthermore, the putative mechanisms of action will be dis-
cussed.
CUTANEOUS T CELL LYMPHOMA (CTCL)
CTCL is a clonal lymphoid malignancy of helper T lymphocytes
(CD41). Initial signs of this disease usually appear in the skin as
plaques, tumors, or erythroderma, occasionally with concomitant
lymphadenopathy and circulating malignant T cells. As the disease
progresses, peripheral blood, nodal, and visceral involvement usually
become more frequent and extensive. Although a variety of therapies
directed at the cutaneous manifestations of CTCL, including electron
beam radiation, topical mechlorethamine, as well as conventional
psoralen and ultraviolet A photochemotherapy (PUVA), yield a high
rate of initial clinical responses in regard to the skin disease (Thomsen
et al, 1989; Vonderheid et al, 1989), these therapeutic regimens appear
to produce little effect on extracutaneous disease. Furthermore, although
multidrug chemotherapy has been recommended for advanced CTCL
characterized by multiple tumors, erythroderma, or Sezary syndrome,
it does not prolong survival and is associated with a substantial degree
of morbidity (Kay et al, 1989). Thus, the initial multicenter trial of
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photopheresis conducted by Edelson et al that used this therapy on
two successive days monthly for the treatment of erythodermic CTCL,
yielded highly beneficial results with few, if any associated adverse
effects (Edelson et al, 1987). Twenty-four of 29 (83%) erythrodermic
patients, with disease resistant to a variety of conventional therapies,
had improvement in their erythroderma with a mean time to develop-
ment of a positive response within the skin of 22.4 wk. Moreover,
nine patients (24%) experienced better than a 75% improvement in
extent of their skin lesions, whereas 13 patients (35%) had a 50%–75%
improvement in their skin lesions. Patients with the most significant
degree of improvement had experienced noticeable clearing of their
skin by the third or fourth month of treatment.
Emerging data from multiple treatment centers further substantiates
a significant response rate achieved using photopheresis as monotherapy
for patients with advanced CTCL. Gottlieb et al observed a 71%
response rate, with a 25% complete response rate among 28 patients
who received photopheresis monotherapy for at least 6 mo, the
majority of whom had Sezary syndrome (Gottlieb et al, 1996).
Furthermore, in a review of her recent clinical experience, Duvic et al
reported a 50% overall response rate and an 18% complete response
rate among 34 patients, 28 of whom had erythrodermic CTCL (Duvic
et al, 1996). Thus, patients with Sezary syndrome or erythroderma
appear to have frequent responses to photopheresis when this therapy
is employed on at least two consective days every 4 wk.
In addition to improvement in the cutaneous manifestations of
CTCL, a decrease in the extent of peripheral blood involvement has
also been observed at different centers (Edelson et al, 1987; Duvic et al,
1996; Gottlieb et al, 1996). Among responders who have increased
numbers of CD41 peripheral blood cells prior to therapy, the majority
experienced a significant drop in the absolute numbers of these cells
during their therapy. This decrease likely indicated a drop in the
numbers of circulating malignant cells that bear CD4 on their surface.
This conclusion is supported by the observation of Gottlieb et al that
the numbers of atypical cells within the peripheral blood with a
cerebriform nuclear morphology (Sezary cells) also decreased. Among
the seven patients monitored by Gottlieb with Sezary syndrome
who experienced complete responses, circulating Sezary cells became
undetectable and T cell receptor gene rearrangement studies utilizing
either Southern blot analysis or more sensitive polymerase chain
reaction (PCR) assays have indicated the disappearance of the malignant
clone from their peripheral blood in response to photopheresis therapy
(Gottlieb et al, 1996; Lessin et al, 1991).
Long-term follow-up of erythrodermic patients who received photo-
pheresis have suggested that this therapy may prolong survival beyond
that expected with conventional therapies (Heald et al, 1992; Gottlieb
et al, 1996). Gottlieb et al determined that survival of their patients
exceeded 100 mo from the time of diagnosis of their disease, whereas
previous studies of a comparable patient population, using established
therapies other than photopheresis, have revealed survival rates of 30–
40 mo (Sausville et al, 1988). A recent uncontrolled study failed to
observe a statistically significant survival advantage of Sezary syndrome
patients who received photopheresis as monotherapy (Fraser-Andrews
et al, 1998). It is noteworthy, however, that many of the patients had
received prior treatment with agents that clearly suppress the immune
response, including cyclophosphamide, chlorambucil, fludaribine, and
multidrug chemotherapy. Such pretreated patients have never
responded to photopheresis monotherapy at our center. Typically, an
immune adjuvant, such as interferon-α added to photopheresis, is
necessary to induce a response in this setting (see below). Appropriate
prospective controlled trials comparing photopheresis to other thera-
peutic agents for advanced CTCL, although difficult due with the
paucity of patients with advanced disease, are still warranted to
determine the full nature of the potential survival advantage produced
by photopheresis.
During this period of extended observation, there have been few
adverse effects of photopheresis recorded. These results are remarkable
in view of recent data demonstrating not only a failure to prolong
survival of CTCL patients with the use of intensive multidrug chemo-
therapeutic regimens combined with electron beam irradiation, but
also in light of the high degree of morbidity of such treatment (Kay
Table I. Profile of CTCL photopheresis responders
Presence of modest or small numbers of peripheral blood Sezary cells
(10%–20% of mononuclear cells)
Short duration of disease (less than 2 y)
Normal or near normal numbers of cytotoxic T lymphocytes
Normal natural killer cell activity
No prior history of intensive chemotherapy
Absence of bulky lymphadenopathy or overt visceral disease
Table II. Potential indications for photopheresis
Advanced cutaneous T cell lymphoma (FDA approved)
Allograft rejection
Graft versus host disease
Immunosuppressive drug resistant bullous disease
Systemic lupus erythematosus
Systemic sclerosis
Table III. Potential mechanisms of action of photopheresis
Induction of T cell apoptosis
Macrophage/dendritic cell activation leading to enhanced processing of
apoptotic T cell antigens and release of proinflammatory mediators
Induction of anticlonotypic immunity by the above processes
et al, 1989). Because of the paucity of adverse effects associated with
photopheresis, as well as the potential for the prolongation of life, we
frequently employ photopheresis as an initial therapy, along with other
adjunctive biologic therapies including recombinant interferon-α, for
CTCL patients with peripheral blood involvement.
Our experience during the last 13 y, and that of other investigators
(Heald et al, 1992), has formed the basis for the development of a
clinical profile of those patients most likely to respond to this therapy
(Table I). We routinely recommend this treatment for patients who
have either morphologic or Southern blot evidence of circulating
malignant cells. Thus, patients with the Sezary syndrome or individuals
with extensive plaque disease who have the presence of atypical
peripheral blood cells observed on one micron-section analysis of buffy
coat specimens, characterized by cerebriform nuclear morphology, are
considered to be excellent candidates for photopheresis. In contrast,
those without evidence of malignant peripheral blood cells as assessed
using multiple parameters including one micron-section buffy coat
analysis, gene rearrangement studies, or flow cytometry, have failed to
respond at our institution to photopheresis monotherapy. For example,
no patients with plaque disease covering greater than 10% of the skin
surface area, or with erythroderma, in the absence of peripheral blood
involvement, have responded to photopheresis. This is in contrast to
patients with a similar degree of skin involvement in the presence
of peripheral blood involvement, who have had substantial clinical
improvement at our institution. Furthermore, those with an especially
large tumor burden (white blood count .20,000 per mm3, widespread
bulky lymphadenopathy, visceral disease, or numerous cutaneous
tumors) are unlikely to respond to photopheresis used as a single
treatment modality. Although the authors are aware of several cases of
tumor stage disease that have improved while undergoing photopheresis
treatment, this form of CTCL is a good example of the need for
concurrent therapy with electron beam irradiation with or without
interferon-α (see below).
The overall integrity of the cell-mediated immune response is
believed to be a critical factor for patient responsiveness to photopher-
esis. Our results indicate that normal levels of peripheral blood CD81
cytolytic T cells and natural killer cell activity are usually detected
among patients with prominent clinical responses, whereas low levels
of CD81 T cells and natural killer cell activity are typically measured
among nonresponders. These results imply that CD81 cytolytic T cells
and natural killer cells may be important components of the antitumor
immune response. Moreover, these data may reflect the requirement
for a greater degree of immune integrity so as to be able to generate
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an immune response against the photo-altered malignant cells. These
observations are highly relevant to the recent findings that the malignant
clonal T cell population in CTCL may be susceptible to cell-mediated
lysis by autologous cytotoxic T lymphocytes (Berger et al, 1996). Thus,
strategies directed at the immunologic enhancement of cytotoxic T
lymphocyte function through the use of biologic response modifiers
may improve the efficacy of photopheresis (see below).
The use of immunosuppressive agents can exert a negative impact
on the ability to generate an antitumor immune response. Thus,
the extent of prior treatment with immunosuppresive chemotherapy
negatively correlates with response to photopheresis therapy. (Previous
immunosuppression in transplant patients experiencing active rejection
and in marrow allograft recipients with graft versus host disease,
however, does not appear to alter the response to photopheresis as
described below.) In fact, studies using animal models of photopheresis
have suggested that corticosteroids or immunosuppressive agents can
inhibit the desired immunologic effects of this therapy, whereas
granulocyte-macrophage colony stimulating factor (GMCSF) can
enhance the response to photopheresis (Perez and Edelson, personal
communication). Corticosteroids are known to inhibit host immune
responses, including natural killer cell activity and production of
GMCSF and tumor necrosis factor-α (TNF). Treatment-induced TNF,
and perhaps GMCSF, may be important components of the antitumor
response. We have recently determined that photopheresis induces the
marked production of TNF and GMCSF by treated monocytes (Vowels
et al, 1992; Rook, unpublished results). As a further example of
photopheresis-induced immune responses that may be impaired by
drugs, we attempt to avoid the use of prednisone in our CTCL
patients. It is for reasons such as these that we advocate, whenever
possible, the use of immune enhancing agents such as interferon-α rather
than potentially immunosuppressive drugs for patients with CTCL.
For patients with disease parameters that place them in a poor
prognostic category and that suggest a low probability of having a
therapeutic response to photopheresis (extensive prior chemotherapy,
large tumor burden, low numbers of peripheral blood CD81 T cells,
depressed natural killer cell activity), adding certain adjunctive therapies
in combination with photopheresis may improve the clinical course.
We have obtained excellent results using interferon-α in low doses in
combination with photopheresis. Patients are started on 2–2.5 million
units subcutaneously three times weekly to minimize flu-like symptoms.
Doses are gradually increased, as tolerated, to 5–7.5 million units four
to five times weekly. The most typical regimen consists of 3–5 million
units every other day. The majority of patients treated in this manner
have experienced a significant drop in the numbers of circulating
atypical cells in association with improvement in skin disease. In fact,
a review of CTCL patients treated at our institution revealed that
11 of 14 patients experienced significant improvement following
supplementation of their photopheresis regimen with interferon.
Although the interferon is likely playing an exceedingly important role
in these responses, it is the authors opinion that the two therapies
appear to have an additive benefit over either alone.
Other biologic response modifiers that deserve exploration in
combination with photopheresis include interferon-γ, interleukin-12
(IL-12), and GMCSF. Interferon-γ and IL-12 exert substantial immune
augmentatory effects on cytotoxic T lymphocyte function. Further-
more, the lymphocytes of patients with CTCL exhibit striking defects
in the ability to produce these cytokines (Rook et al, 1993, 1995). A
phase I trial using recombinant IL-12 alone for the treatment of CTCL
has demonstrated a high clinical response rate and induction of cytotoxic
T cell activity at sites of regressing lesions (Rook et al, 1999). Thus, if
a vaccination effect of photopheresis with the subsequent generation
of antitumor cytotoxic T cell responses is proposed as a primary
mechanism of action (see below under mechanisms), then the concomit-
ant use of IL-12 could potentially enhance this beneficial response. In
addition, photopheresis is known to induce a high rate of apoptotic
death of malignant T cells within the blood and it is presumed that
antigens from these T cells are processed by the host immune response
(Yoo et al, 1996). The administration of GMCSF following the
photopheresis procedure might then increase the ability of antigen
presenting cells to process antigenic components of cells undergoing
apoptosis, leading to an augmented response to photopheresis. At least
two patients at our center have had significant clinical improvement
associated with the initiation of GMCSF therapy administered in a
dose of 125 micrograms subcutaneously 1 h post-photopheresis.
Other adjuntive therapies used in combination with photopheresis
include electron beam therapy that is frequently used at our institution
as a debulking procedure for patients with large cutaneous tumors
(Jones et al, 1995). Although there are anecdotal reports of patients
with tumors who responded to photopheresis alone, in our experience
concomitant electron beam therapy, often with interferon-α, is usually
required to produce tumor flattening. Use of methotrexate in doses of
15–25 mg weekly or azathioprine daily have also been suggested for
patients with elevated white blood cell counts. Although these drugs
may provide benefit by impeding the in vivo proliferation of the
malignant T cells, one must also consider their potential for suppression
of the host response to the photo-altered tumor cells induced by
photopheresis. Finally, the use of other skin directed therapies, including
topical mechlorethamine, topical carmustine, and PUVA therapy have
all been found to be valuable adjuncts to clear the skin of patients who
respond slowly to the combinations of agents described above.
ALLOGRAFT REJECTION
As a novel alternative to the use of potent immunosuppressive drugs,
striking results have been obtained by several groups using photopheresis
to reverse acute rejection of heart allografts (Table II). Costanzo-
Nordin et al at Loyola University were able to rapidly reverse eight of
nine acute rejection episodes among seven cardiac allograft recipients
using photopheresis (Costanzo-Nordin et al, 1992b). In most cases,
one treatment, and no more than two photopheresis treatments, were
capable of arresting the rejection episodes. Moreover, no serious adverse
effects of treatment were observed among this patient population. In
a subsequent randomized trial, this same group of investigators compared
a single photopheresis treatment witth 3 d of high dose systemic
corticosteroids in their ability to reverse cellular rejection of transplanted
hearts (Costanzo-Nordin et al, 1992a). Following randomization and
treatment of 16 patients, a comparable high rate of reversal of rejection
occured within both groups with no significant differences being
observed in response rate between the two groups.
In the experience of the authors, acute rejection should be treated
aggressively at the outset with treatments on two consecutive days
weekly for the first 2 wk and then on two consecutive days every
other week until the rejection has resolved or improved significantly.
Utilizing this regimen, eight of eight cardiac allograft recipients
experiencing severe cellular rejection unresponsive to immunosuppres-
sive drugs have had their rejection reversed at our institution (Macey
et al, 1994; DeNofrio et al, 1999; unpublished results). Similarly, recent
reports have indicated that intensive photopheresis therapy of refractory
lung or renal allograft rejection can produce a high response rate with
reversal of the acute rejection (Dall’Amico et al, 1997; Slovis et al,
1995; Wolfe et al, 1996).
Barr et al have also employed photopheresis on a prophylactic basis
in an effort to prevent the manifestations of acute graft rejection among
cardiac allograft recipients (Barr et al, 1998). They reported on a total
of 61 patients, 27 of whom received standard triple drug therapy and
34 of whom received 24 photopheresis treatments during the first 6
mo post-transplantation in addition to standard therapy. Following 6
mo of treatment, the rate of acute rejection was significantly reduced
among patients in the photopheresis group in comparison with the
standard therapy group. Furthermore, those who received standard
therapy had a significantly higher frequency of multiple rejection
episodes. It is noteworthy that the incidence of infection was actually
lower in the group receiving combined therapy. This latter observation
likely reflects the diminished need for supplemental immunosuppressive
therapy to treat acute rejection. Thus, the results of this study establish
photopheresis as an important immunotherapy that can significantly
decrease the frequency of rejection following cardiac transplantation.
Convincing new data has recently been presented suggesting that
photopheresis can be a useful adjunctive therapy following allogeneic
bone marrow transplantation to reverse graft versus host disease (GVH)
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(Dall’Amico et al, 1998; Greinix et al, 1998). Greinix et al have
reviewed the largest series including 21 patients, 15 of whom had
chronic GVH and six of whom had acute GVH. An intensive treatment
regimen comparable with that recommended for acute cardiac allograft
rejection resulted in complete resolution of GVH in 12 of 15 with
chronic disease and four of six with acute GVH, including normalization
of hepatic dysfunction in seven of 10 cases (Greinix et al, 1998).
These data strengthen the notion that controlled trials employing
photopheresis to treat allograft rejection and GVH are urgently needed
to unequivocally demonstrate the utility and safety of this therapy post-
transplantation.
AUTOIMMUNE DISEASE
Photopheresis has been used for a diverse group of autoimmune diseases
with encouraging results (Table II). An initial study using photopheresis
to treat autoimmune disease produced favorable results in patients
with pemphigus vulgaris who were resistant to corticosteroids and
immunosuppressive drugs (Rook et al, 1990). Four patients with
uncontrolled disease, despite prolonged courses of treatment with
high doses of prednisone in combination with cyclophosphamide or
azathioprine, responded to photopheresis. All patients initially had
improvement in the extent of their skin disease that allowed for
significant tapering of other medications. Three of the four patients
eventually experienced long-term remissions permitting discontinu-
ation of all treatment. Significant reductions in serum levels of
antiepidermal cell immunoglobulin G occured in conjunction with
clinical improvement. Although relapses occured in all three, remission
was easily reinduced following three to four additional monthly cycles
of photopheresis. It is our experience that once clinical improvement
occurs, gradual tapering of corticosteroids and immunosuppressive
medications can proceed; however, simultaneous abrupt tapering of
photopheresis along with the tapering of other medications may result
in the early reoccurence of skin lesions. Photopheresis produced no
serious adverse effects in any of the four patients during several years
of follow up.
Recently, photopheresis has been successfully employed to treat
systemic sclerosis (Rook et al, 1992). Substantial skepticism has arisen
regarding the use of photopheresis for systemic sclerosis because it
manifests primarily as a fibrosing disease with increased deposition of
collagen within the skin and involved visceral organs. Despite its status
as a fibrosing disease, recent observations have implicated the immune
system as a prime factor in the genesis of the increased collagen
production (Kahaleh and Roy, 1989; Kahari et al, 1990). Elevated
serum levels of soluble interleukin-2 receptors in patients with active
clinical disease support the association of T cell activation with disease
progression. Furthermore, biopsy of involved tissues early in the
evolution of the clinical disease has revealed tissue infiltration with
activated helper T cells that may be releasing certain cytokines,
particularly transforming growth factor β, which is a potent stimulator
of collagen synthesis (Kulozik et al, 1990). Moreover, use of sensitive
polymerase chain reaction technology has yielded results suggesting
that a high proportion of patients with systemic sclerosis may have
expanded clonal T cell populations in the peripheral blood, which
may be responsible for mediating the fibrosing process (Lessin and
Rook, unpublished observations).
The results of a multicenter randomized, single-blinded trial to
examine the efficacy and safety of photopheresis in the reversal and
prevention of progression of skin disease in systemic sclerosis of recent
onset and rapid development, have recently been published (Rook
et al, 1992). Seventy-nine patients with systemic sclerosis of recent
onset (mean duration of symptoms was 1.83 y) and progressive
skin involvement entered a randomized, parallel group clinical trial
comparing photopheresis given on two consecutive days every 4 wk
to treatment with D-penicillamine. Skin severity scores (skin hardening),
percentage skin surface area involvement, hand closure, and oral
aperture were evaluated monthly by blinded examiners. A variety of
other evaluations including pulmonary function tests, skin biopsies,
and serologies were obtained at baseline and after 6 and 12 mo of
treatment. During this trial 56 patients received 6 mo of therapy (31
received photopheresis), whereas 47 received 10 mo of therapy (29 on
photopheresis). By 6 mo of treatment, 21 of 31 (68%) patients who
received photopheresis had experienced significant softening of the skin,
in comparison with eight of 25 (32%) who received D-penicillamine. It
is noteworthy that whereas only three of 31 (10%) of those who
received photopheresis had experienced significant worsening of their
skin severity score after 6 mo of treatment, eight of 25 (32%) who
received D-penicillamine had significant worsening. Thus, in the early
phases of treatment, a significantly higher response rate was obtained
with photopheresis (p 5 0.02). At both the 6 and 10 mo evaluation
point, the mean skin severity score, mean percentage involvement,
and mean oral aperture measurements were significantly improved
from baseline among those who received photopheresis. Mean right-
and left-hand closure measurements had also improved significantly by
10 mo of therapy. Skin biopsy studies demonstrated an association
between clinical improvement and decreased thickness of the dermal
layer.
It is noteworthy that adverse effects of photopheresis were minimal
during this trial and did not require discontinuation of treatment by
any of the patients. In contrast, 25% of patients who received D-
penicillamine were required to permanently discontinue this drug due
to side-effects or rapid progression of disease while on this therapy.
Thus, photopheresis appears to produce early improvement with few
side-effects when used for aggressive cases of recent onset systemic
sclerosis.
In addition to studies involving pemphigus and systemic sclerosis,
the results of pilot studies have suggested the potential efficacy
of photopheresis for rheumatoid arthritis (Malawista et al, 1991),
epidermolysis bullosa acquisita (Miller et al, 1995; Gordon et al, 1997),
atopic dermatitis (Prinz et al, 1994), and systemic lupus erythematosus
(Knobler et al, 1992). Other clinical indications that have been studied
where efficacy has not been demonstrated include multiple sclerosis,
chronic hepatitis C, and AIDS-related complex.
ADVERSE EFFECTS
The general experience since 1985 is that photopheresis has been
extremely well tolerated. The most common adverse effect has been
the sporadic occurence of psoralen-induced nausea. This is usually
mild with a short duration of 30–60 min. It occasionally can be
associated with vomiting and diaphoresis. If nausea is recurrent, the
dosing can be staggered. For example, each 10 mg capsule can be
administered every 10 min. This split dose regimen typically produces
satisfactory blood levels within 2 h after the last capsule, yet nausea
often can be eliminated. The recent FDA approval of a new liquid
form of psoralen that can be mixed directly with the leukocytes within
the UVAR device, which will permit the precise pharmacologic
regulation of 8-MOP levels, will obviate the need for oral administration
of 8-MOP in the future (Knobler et al, 1993).
Hypotension occurs uncommonly during the leukapheresis phase,
particularly among those taking antihypertensive agents or diuretics.
These medications are often held until the conclusion of the treatment.
As an alternative, small volumes of normal saline may be infused just
prior to the initiation of the treatment as a preventive measure. In
most cases, patients with advanced cardiomyopathy and aortic stenosis
have tolerated photopheresis without difficulty. These observations
indicate that substantial homeostatic derangements of vascular volume
are often required for the development of hypotension.
Low grade fevers occuring 4–12 h after reinfusion of the treated
cells are common during the early phases of therapy in patients with
CTCL. Patients are usually asymptomatic and antipyretics are not
needed. Fever appears to be unrelated to bacteremia and is associated
with the most marked clinical responses to treatment. Recent observa-
tions indicate that photopheresis is responsible for the induction of
proinflammatory and pyrogenic cytokines from monocytes (see below).
This immunologic effect is the likely cause for the post-treatment
febrile response. Nevertheless, because this therapy involves venous
cannulation of the frequently immunosuppressed patient, it is recom-
mended that blood cultures be obtained and that all potential sources
of infection be evaluated.
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Although normal leukocytes are exposed to psoralen and ultraviolet
during the photopheresis procedure itself, depletion of these blood
elements has not been noted. Furthermore, clinical evidence of
photopheresis-induced immunosuppresion such as the development of
neoplasia or opportunistic infections, has not been observed. Thus the
fact that photopheresis produces minimal adverse effects and can
provide substantial benefit indicates that this therapy has clear advantages
in comparison with chemotherapeutic and immunosuppressive agents.
MECHANISM OF ACTION OF PHOTOPHERESIS
Substantial new information has emerged that suggests that photopher-
esis exerts its clinical effects via several mechanisms of action (Table
III). The biologic effects of psoralens are critical to the treatment
process. 8-MOP rapidly diffuses into nucleated cells and upon exposure
to ultraviolet A irradiation, covalent cross-linking of DNA occurs that
ultimately results in the proliferative arrest of treated cells (Song and
Tapley, 1979). Furthermore, the combination of 8-MOP and ultraviolet
A irradiation causes the majority of treated T cells to undergo apoptosis
within 48 h of the photopheresis procedure (Yoo et al, 1996).
Because large or activated T cells may be particularly sensitive to the
antiproliferative effects of 8-MOP and ultraviolet A, such T cells
within the peripheral blood of patients with autoimmune disease or
allograft rejection may be especially susceptible targets for psoralen and
ultraviolet A-mediated damage.
Although a high rate of apoptosis of treated T cells occurs after
exposure to at least 50 ng 8-MOP per ml and 2 J per cm2 of ultraviolet
A irradiation, peripheral blood macrophages appear to be comparatively
resistant to the apoptotic effects of 8-MOP and ultraviolet A (Yoo
et al, 1996). Moreover, upon completion of the photopheresis proced-
ure, treated monocytes appear to have an activated phenotype with
enhanced expression of proinflammatory cytokines, adhesion molecules,
and major histocompatibility proteins that are essential for antigen
presentation (Vowels et al, 1992; Moor et al, 1995). In fact, flow
cytometry studies have revealed that the critical accessory molecule
CD86 and the adhesion molecule CD36 are routinely and rapidly
upregulated on the surface of macrophages upon completion of
photopheresis (Fimiani et al, 1997; Kao and Rook, unpublished
observations). These findings are undoubtedly relevant to the observa-
tion that photopheresis-treated macrophages exhibit a significantly
increased ability to phagocytose apoptotic T cells (Yoo et al, 1996). Thus,
one could invoke the enhanced uptake, processing, and presentation by
macrophages and dendritic cells of apoptotic T cell antigens from
dominant clones of pathogenic T cells as a possible scenario for
the induction of anticlonotypic immunity by photopheresis (Albert
et al, 1998).
Evidence that photopheresis induces anticlonotypic immunity has
been suggested by recent observations using a number of different
experimental animal models. Study of the murine model of experimental
allergic encephalitis has been especially revealing in this regard (Khavari
et al, 1988). In this model, rats injected with myelin basic protein
develop a paralytic illness associated with T cell destruction of the
nervous system. The pathogenic T cells that mediate this destruction
can be isolated and cloned in vitro. When naı¨ve syngeneic rats are
inoculated with the cloned T cells, all of the features of experimental
allergic encephalitis are reproduced. If the pathogenic clones are first
treated with psoralen and ultraviolet A and then infused, however, the
animals are protected from the development of disease upon subsequent
challenge with the pathogenic T cells. Protection from disease appears
to be mediated by the generation of clone-specific suppressor T cells
that have developed in response to the psoralen and ultraviolet A-
modified pathogenic cells. Perez et al, employing a model of cutaneous
allograft rejection, have similarly obtained evidence of stimulation of
an antigen-specific suppressor T cell response when alloreactive effector
T cells are treated with psoralen and ultraviolet A and infused into
syngeneic animals (Perez et al, 1989). These results indicate that, at
least in the setting of these animal models, an active immunization
process can occur following the administration of photoinactivated
syngeneic T cell clones.
Because of its efficacy in the treatment of diseases of immune
activation, concern has been expressed regarding the potential immuno-
suppressive effects of photopheresis. Studies in our laboratory have
indicated that photopheresis does not produce measurable suppression
of T cell responses against recall protein antigens, such as tetanus
toxoid, nor does it suppress primary immune responses against de novo
protein antigens such as Keyhole Limpet hemocyanin (Suchin et al,
1999). Furthermore, a panel of delayed type hypersensitivity skin tests
placed on seven patients with systemic sclerosis remained unaltered
following 6 mo of photopheresis therapy. It is possible, however,
that photopheresis induces specific suppression of responses against
alloantigens, as suggested by the observations of Perez et al (1989) using
a murine model of cutaneous allografting. These latter observations are
particularly relevant to the early clinical findings that photopheresis
can reverse rejection of transplanted hearts. Nevertheless, it should be
emphasized that significant clinical evidence of photopheresis-induced
immunosuppression, such as the development of neoplasia or opportun-
istic infections, has not been observed. Moreover, when used in the
already heavily immunosuppressed populations that have received solid
organ or bone marrow allografts, an increased frequency of bacterial
infections has not been observed. Thus, the fact that photopheresis
produces minimal adverse effects and provides substantial benefit for a
number of immune mediated diseases, indicates that this therapy
has clear cut advantages in comparison with chemotherapeutic and
immunosuppressive agents in the treatment of these conditions.
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